The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 12, 2026 for Renosen Pharmaceuticals ....
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Renosen Pharmaceuticals Private Limited, a promoter entity of Senores Pharmaceuticals Ltd, has submitted a revised SAST disclosure regarding the release of a pledge on 4,00,000 (four lakh) equity shares, which represents 0.87% of the total share capital. The release was made on February 13, 2026, in favor of Bajaj Finance Limited. After this release, Renosen Pharmaceuticals' encumbered holding has come down to zero. The revision was made because the earlier disclosure (dated February 16, 2026) did not include the reason for encumbrance, which has now been provided.
This is a positive development for shareholders as the release of pledged shares reduces encumbrance risk on promoter-held stock. Post-release, Renosen Pharmaceuticals has no pledged shares, indicating improved promoter financial health and lower risk of forced selling.